The eradication of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) predicts for improved outcome. However, the wide variety of MRD techniques makes it difficult to interpret and compare different clinical trials. Our aim was to develop a standardized flow cytometric CLL-MRD assay and compare it to real-time quantitative allele-specific oligonucleotide (RQ-ASO) Immunoglobulin heavy chain gene (IgH) polymerase chain reaction (PCR). Analysis of 728 paired blood and marrow samples demonstrated high concordance (87%) for patients off-therapy. Blood analysis was equally or more sensitive than marrow in 92% of samples but marrow analysis was necessary to detect MRD within 3 months of alemtuzumab therapy. Assessment of 50 CLL-specific antibody combinations identified three (CD5/CD19 with CD20/CD38, CD81/CD22 and CD79b/CD43) with low inter-laboratory variation and falsedetection rates. Experienced operators demonstrated an accuracy of 95.7% (specificity 98.8%, sensitivity 91.1%) in 141 samples with 0.01-0.1% CLL. There was close correlation and 95% concordance with RQ-ASO IgH-PCR for detection of CLL above 0.01%. The proposed flow cytometry approach is applicable to all sample types and therapeutic regimes, and sufficiently rapid and sensitive to guide therapy to an MRDnegativity in real time. These techniques may be used as a tool for assessing response and comparing the efficacy of different therapeutic approaches. Leukemia (2007) 21, 956-964.
Introduction
Recent therapeutic approaches using fludarabine-based regimens combined with monoclonal antibodies (e.g. rituximab or alemtuzumab) or autologous transplantation are associated with improved response rates with 50-70% of patients achieving an National Cancer Institute (NCI)-complete remission. [1] [2] [3] [4] [5] [6] [7] [8] [9] In addition, these approaches have been associated with eradication of detectable disease in a significant proportion of patients. Several studies demonstrate that chronic lymphocytic leukaemia (CLL) patients achieving eradication of detectable minimal residual disease (MRD), determined by a highly sensitive technique, have prolonged survival and that morphological response criteria are not sufficiently sensitive to assess outcome. [9] [10] [11] After alemtuzumab therapy, sustained remissions only occur in patients achieving an MRD-negative response whereas patients achieving an MRD-positive complete response appear to have the same overall survival as those achieving only a partial response to alemtuzumab. 12 Therefore, MRD is increasingly being used as an end point for therapeutic trials, and several studies are now using the assessment of MRD to define the duration of therapy.
There are many approaches to measuring MRD in CLL. The simplest approaches are CD19/CD5 co-expression analysis, assessment of light chain restriction by flow cytometry and consensus primer polymerase chain reaction (PCR) analysis of the immunoglobulin heavy chain gene (IgH-PCR). 13, 14 These approaches are not directly quantitative and have a low and variable sensitivity: a sample classified as being MRD-negative by one technique may have 100 times more disease than a sample classified as being MRD-positive by more sensitive techniques. 10, [15] [16] [17] Comparing the efficacy of different clinical trials requires a directly quantitative approach to residual disease analysis. Approaches using allele-specific oligonucleotide PCR to the immunoglobulin gene of the B-CLL cell are generally accepted to show the highest sensitivity for MRD detection. 15, 16 The BIOMED-2 concerted action group have identified standard PCR primers that are suitable for detection and monitoring of patients with CLL. 18 However, real-time quantitative allele-specific oligonucleotide (RQ-ASO) IgH-PCR results are often not available within a time frame suitable for making therapeutic decisions and the technique is laborious and initially expensive. Four-colour flow cytometric approaches have a more rapid turn-round time suitable for this application and show sensitivities nearing that of RQ-ASO IgH-PCR. 10, 15, 16 There have been a wide variety of MRD flow assays reported and most rely to some extent on assessment of CD20 expression, which may be compromised during rituximab therapy. [19] [20] [21] In order to allow direct comparison of the different approaches, it is necessary to develop a consensus reagent set that can be used in peripheral blood and bone marrow at all stages of the disease and independent of the therapeutic approach.
Therefore, the aim of this project was to develop a standardized method for MRD analysis by flow cytometry that could be performed by most centres; that has a defined specificity and sensitivity; and that uses a standard reporting convention. The application of this assay would allow the direct comparison of RQ-ASO IgH-PCR and flow cytometry results from different laboratories. The consensus MRD flow assay will provide a tool for guiding assertive therapy and for assessing response, allowing direct comparison of efficacy in clinical trials.
Methods

Patients
Patient material used in this study was from patients with a diagnosis of CLL according to NCI-Working Group (WG) criteria, from normal blood donors, or from patients undergoing investigation for an unrelated haematological disorder with no evidence of CLL. In all cases, patients provided informed consent for peripheral blood and/or bone marrow samples to be taken for investigation. Samples were anonymized and no patient-identifiable information was recorded as part of this study. Analysis was performed according to specific research ethics protocols or under local guidelines for secondary use of anonymized waste material.
To compare peripheral blood and bone marrow samples for the detection of MRD, CLL cell levels from paired blood and marrow samples were determined at one of three centres from patients during or after therapy with (i) CHOP or F-like cytoreduction followed by DexaBEAM and SCT after myeloablative TBI/cy conditioning analysed by RQ-ASO IgH-PCR in 282 samples; (ii) FCM or CHOP þ /Àautologous SCT analysed by flow cytometry (n ¼ 148) þ /ÀRQ-ASO IgH-PCR (n ¼ 100); or (iii) Alemtuzumab þ /Àautologous SCT or fludarabine, analysed by flow cytometry in 198 samples. The approaches used and clinical outcome where applicable have been reported previously. 6, 9, 10, 12, 15, 16, 22 Flow cytometry Samples were prepared using participating laboratories standard procedures, but all antibody combinations were tested as a minimum with a whole-blood post-antibody lyse/wash and a pre-antibody ammonium chloride red cell lysis approach. The post-antibody lyse/wash preparation was performed using FACSLyse according to the manufacturer's protocol (BDIS, www.bdbiosciences.com). Ammonium chloride lysis was performed by incubating whole blood or marrow with a 10-fold excess of ammonium chloride (8.6 g/l in distilled H 2 O) for 10 min, centrifuging the leucocytes at 300 g for 5 min and washing twice in 15 ml of buffered saline solution, for example FACSFlow (BDIS) containing 0.3% bovine serum albumin (Sigma-Aldrich, www.sigmaaldrich.com); 1 Â 10 6 leucocytes were stained with the appropriate volume of pretitred antibody for 20 min at 41C in the dark, and washed twice then resuspended in a suitable medium for acquisition.
The antibody combinations tested are shown in Table 1 . Combinations highlighted in bold were selected for further assessment and the following clones and conjugates were used.
CD45:
2D1 FITC (BDIS) CD3:
SK7 APC (BDIS) Kappa:
TB28-2 FITC (BDIS) Lambda:
1-155-2 PE (BDIS) Samples from presentation/relapse CLL patients were assessed using a standard diagnostic panel (incorporating at least CD19, CD5, CD23, CD20, CD79b, kappa and lambda) to identify the proportions of CLL cells whereas control samples were assessed using one of the previously reported MRD approaches to ensure that CLL cells were not detectable. 10, 15, 16 For each case, three different samples were prepared: an extensive disease sample containing undiluted leucocytes from patients with progressive disease in which more than 50% of leucocytes were CLL cells; a minimal disease sample containing CLL cells diluted into the control sample such that the CLL cells represented 0.1-0.5% of total leucocytes, or 5-30% of total B cells; and a disease-free sample containing cells from normal donors only. The extensive disease, disease-free and minimal disease samples were prepared for seven cases, and an aliquot of each sample was incubated with each of the nine antibody combinations under assessment and also kappa/lambda/CD19/CD5, that is, 30 tests (10 antibodies in three settings) for each case. The data were acquired centrally, pre-gated on B cells to minimize variation produced by the gating strategy and distributed electronically to participating centres. Centres were requested to identify the proportions of CLL cells and normal B cells in each sample. Inter-laboratory variation was defined as 100 Â s.d./mean for the CLL cell percentage of B cells.
To determine whether factors before data acquisition including specimen transport and preparation affect MRD analysis, simulated samples containing 0.01-0.1% CLL cells and a normal blood sample were prepared, aliquoted and sent to three or four participating centres by next day courier. Samples were prepared using the same antibody panel but with local preparation methods at the participating centres. Ungated electronic data files were then distributed to allow comparison between electronic data and fresh samples for quality control purposes.
For comparison of flow cytometry and RQ-ASO IGH-PCR, samples from three dilutional series containing known proportions of CLL cells (ranging from 0.0001 to 91%) and from patient samples undergoing or after treatment with six courses of FC (n ¼ 12) or FCR (n ¼ 23) were analysed in parallel by flow cytometry and by RQ-ASO IGH-PCR. In all tests, participants were requested to indicate the number of events acquired, the CD45 þ cells, CD3 þ cells, CD19 þ cells, contaminating events (i.e., the number of CD3 þ events within the B-cell gate) and CLL cells for each tube of the combination employed.
Real-time quantitative allele-specific oligonucleotide immunoglobulin heavy chain gene PCR (RQ-ASO IgH-PCR)
RQ-ASO IgH-PCR was performed as reported previously. 15, 16 Briefly, genomic DNA was isolated and amplified according to the BIOMED-2 protocol;
18 PCR products were purified and directly sequenced using the BigDye Terminator Cycle Sequencing kit (Big Dye 3.1, Applied Biosystems, www.appliedbiosytems.com) in an automated DNA sequencer (ABI PRISM 3100, Applied Biosystems). Allele specific oligonucleotides (ASO) corresponding to the CDR3 region were designed using the Primer Express software (Applied Biosystems). RQ-ASO IgH-PCR was carried out in an ABI Prism 7700 thermal cycler (Applied Biosystems). DNA from samples with known CLL cell content was serially diluted in pooled polyclonal DNA to generate at least five standards. Specificity and sensitivity was defined as the last dilution with target DNA detectable or, in case of nonspecific amplification, the dilution with cycle threshold (CT) values at least one cycle lower than the lowest CT value found in polyclonal DNA. Each PCR showed a standard curve correlation coefficient of at least 0.95 with a slope of 3.0-3.9, minimum sensitivity was 10 -4 and MRD level calculation was based on comparative CT analysis between follow-up samples and standards. Normalization by parallel amplification of the albumin or b-actin gene allowed calculation of the limit of detection for negative samples and calibration of differences in the amount and quality of DNA in comparison to the standard DNA at diagnosis. 23 
Statistical analysis
Statistical analysis was performed using Stata v8.0 (StataCorp, www.stata.com) for Spearman rank correlation and T-test analysis. In all cases, a cutoff of 0.01% was used to define positive and negative except in comparison with RQ-ASO IGH-PCR analysis where analysis according to the limit of detection for individual samples by the RQ-ASO IGH-PCR assay was also assessed. A cutoff of 0.01% was used as this was the operational limit of detection for flow cytometry analysis in the retrospective analysis. In analyses where the actual proportion of CLL cells was known, the following definitions were used: specificity ¼ true negative/(true negative þ false positive), sensitivity ¼ true positive/(true positive þ false negative), accuracy ¼ (true positive þ true negative)/number of tests where true positive is the observed and actual CLL cells 40.01%, true negative the observed and actual CLL cells o0.01%, false positive the observed 40.01% and actual o0.01%, and false negative the observed o0.01% and actual 40.01%. For comparison of blood and marrow, concordance was defined as the proportion of cases in which both blood and marrow samples gave the same result relative to the cutoff level, that is, observed CLL cell proportion 40.01% in both blood and marrow or o0.01% in both. For optimizing specificity by using a standardized protocol for analysis, precision was defined as the proportion of cases in which all operators achieved the same result, that is, all results 40.01% or all results o0.01%.
Results
Use of peripheral blood or bone marrow for residual disease monitoring
In CLL, bone marrow samples are required for response assessment by current NCI criteria, but peripheral blood may be suitable when using MRD flow or RQ-ASO IgH-PCR. MRD levels in 728 paired blood and marrow samples from patients were assessed using previously reported sensitive MRD approaches. 6, 9, 10, 12, 15, 16, 22 Using a cutoff of 0.01% (the limit of detection for flow cytometry methods included in the analysis), concordant results were demonstrated in blood and bone marrow in 579/728 cases (79.5%). Concordance rates varied depending on the treatment type and time since treatment (see Table 2 ).
Samples from patients during or immediately after therapy with regimes containing alemtuzumab gave discrepant results in peripheral blood compared to the bone marrow. In almost all patients treated with alemtuzumab, the proportions of CLL cells in the bone marrow were over 10-fold higher than in the peripheral blood, and usually several thousand-fold higher (median 5014 times higher).
Blood and marrow MRD level concordance was 87.0% (510/ 596) in patients assessed more than 3 months after any treatment, or during therapy with regimes that did not contain alemtuzumab or rituximab. Peripheral blood provided an equally sensitive or more sensitive source for MRD detection than marrow in 537/586 samples (91.6%) from patients not undergoing alemtuzumab therapy. Bone marrow provided an equally or more sensitive source for MRD assessment than blood in 559/586 (95.4%). In cases where both peripheral blood and bone marrow results were within the quantitative range of the flow cytometry or RQ-ASO IGH-PCR assay, there was a highly significant correlation between blood and marrow CLL cell levels (Spearman rank correlation R ¼ 0.8563, Po0.0001). The proportion of CLL cells was a median 1.21-fold higher in the bone marrow than in the peripheral blood. Using a more sensitive technique does not affect concordance: samples assessed by RQ-ASO IGH-PCR showed a concordance of 87.4% (334/382) for detection of CLL cells at any level. These results are shown in Figure 1 .
Identification of suitable antibody combinations for assessment
As there are clearly clinical situations where MRD assessment in the peripheral blood cannot substitute for MRD assessment in the bone marrow, a standardized flow cytometry approach must be applicable to both bone marrow and peripheral blood. We therefore tested a comprehensive range of antibody combinations suitable for separating cells from both mature B cells and normal B-progenitors.
The combinations, listed in Table 1 , were tested on at least three samples with detectable minimal CLL and excluded from further analysis if they provided poorer separation of CLL cells from the background than other combinations. For example, the CD5/CD23/CD43 combination was excluded as CD23 did not provide any additional separation from residual normal CD5 þ B cells, which are predominantly CD23 þ , whereas CD79b/ CD5/CD43 could provide additional separation of CLL cells from normal B cells even in cases with weak CD5. Nine combinations were selected, based on their ability to discriminate B-cell populations, and compared against the most commonly used approach of kappa/lambda/CD19/CD5.
Data files representing extensive disease, minimal disease and disease-free settings using the 10 antibody combinations on seven patients were prepared and distributed. No specific gating strategy was provided. Operators reported CLL cells as a percentage of B cells, and also recorded the percentage of normal B cells that fell within their defined CLL gates. The results are shown in Table 3 . There was general concordance for the proportion of CLL cells identified by the nine different antibody combinations. However, the combinations CD20/ CD38/CD19/CD5, CD22/CD81/CD19/CD5 and CD43/CD79b/ CD19/CD5 showed the lowest inter-lab variability and false positive rate and were therefore chosen as the foundation of the CLL-MRD flow cytometry assay. Plots showing the position of Table 2 Concordance between the detection of residual disease at the level of 0.01% or greater in peripheral blood (PB) and bone marrow (BM) for patients undergoing therapy Optimizing specificity and sensitivity according to the number of events required to define a population.
In order to minimize false-positive results we identified approaches to analysis using a series of 141 data files generated from analysis of simulated minimal disease samples with the above antibody combinations. In this series, 40 sample files contained only normal cells, 32 sample files contained 0.00001-0.01% CLL cells and 69 sample files contained 0.01-0.1% CLL cells.
The accuracy, specificity and sensitivity for detection of CLL was analysed according to the number of events to be used as a minimum required to define a population of CLL cells: either 20, 30, 40, 50 or 100 events. The different operators were requested to determine whether the requisite number of events were present within the CLL regions of all three tests, of two of the tests, or in one test only. In addition, we tested whether specifying a limit of detection for each sample could improve the accuracy of results.
Two factors were used to determine the limit of detection: the contamination rate and the number of events acquired. An estimate of the contamination rate can be derived from the number of CD19 þ events that also bind the CD3 antibody: as CD3 is not expressed by normal B cells or by CLL cells, the percentage of CD19 þ CD3 þ events could be considered as the limit below which it is technically not possible enumerate CLL cells. The total number of events required will directly relate to the minimum number of events used to define a CLL population: to achieve a limit of detection of 0.01%, one must acquire 2 00 000 events if the minimum population size is 20 and 5 00 000 events if the minimum population size is 50. The limit of detection for a sample will be equal to or higher than the contamination rate and/or the minimum population size as a proportion of total events counted.
In the 141 sample files, the median contamination rate was 0.007% of leucocytes (5-95th percentile 0.0006-0.028%) and the median number of leucocytes acquired was 3 25 050 (range 43 519-5 92 353). The contamination level was o0.01% of leucocytes in 110/141 (78%) samples, indicating that the total number of events counted was the limiting factor in the majority of cases. Optimal accuracy and specificity occur when at least 50 CLL events are present in at least two of the three MRD tests, and the result is only classified as positive if the level is above the limit of detection (see Table 4 ). Reduced sensitivity was predominantly caused by acquisition of insufficient numbers of leucocytes: of six samples containing CLL cells above 0.01% that were reported as negative using the 50 event minimum and restricting by limit of detection, 5/6 were limited by event count and only 1/6 by a high contamination rate. Therefore, the optimal approach is to acquire 5 00 000 events.
Optimizing specificity by using a standardized protocol for analysis
To address operator experience, we developed a specific gating strategy and associated protocol. The gating strategy contained detailed instructions on identifying CLL cells and minimizing contamination. In addition, a method was provided for calculating CLL cell levels and limit of sensitivity using the approach described above. This was tested on three operators with experience in diagnostic flow cytometry but not in the analysis of MRD samples using a series of 27 sample data files.
Operators first analysed the files with no prior information provided. The results were recorded, and then the operators read the operating procedures and re-analysed the same files. The numbers of true and false results were recorded. The difference in accuracy, precision, specificity and sensitivity is shown in Figure 3 . The operators produced equivalent results in 11/26 cases before reading the operating procedure, compared with 23/26 cases after reading the operating procedure. In all three discrepant cases, the proportion of CLL cells was low (o0.02%). The use of a standard operating procedure resulted in a 19% improvement in accuracy, and 44% improvement in specificity.
Comparison of electronic data with fresh blood samples for quality control
To determine the variation because of preparation methods, simulated whole-blood samples were prepared and distributed by next-day courier and analysed at the same time in different laboratories. The data recorded in each laboratory were also then transferred between laboratories and re-analysed in a blinded fashion. This was performed for 29 samples containing CLL cells at a level below 0.1%. The median absolute deviation from the known CLL level was À0.0028% (5-95th percentile: À0.055% to þ 0.025%) in the real sample and 0.00% (5-95th percentile: À0.050 to þ 0.040%) for the electronic data, which was not significantly different (paired T-test P ¼ 0.29). Although there are differences in the preparation methods used, these do not appear to add significantly to the level of inter-laboratory variation that is caused by differences in the method of analysis.
Comparative sensitivity and specificity of flow cytometry and PCR approaches
The MRD flow assay was compared against RQ-ASO IgH-PCR strategy in 57 samples from 39 patients (35 diagnostic monitoring samples and 22 dilutional). Concordant results at the 0.01% level were seen in 94.7% of cases (54/57). Two discrepant cases were PCR þ FlowÀ (actual CLL level 0.02%) and one case PCR-Flow þ (flow result 0.01%, PCR result 0.002%). At the 0.01% level, both flow cytometry and PCR have very similar efficacy for the detection of CLL cells. These results Table 3 Inter-operator variability and false-positive rate for nine selected antibody combinations in comparison to kappa/lambda/ CD19/CD5 analysis
Antibody combination
Inter-operator variability 
Table 4
Relationship between accuracy, sensitivity, specificity and limit of detection and the number of events used to define a population Results that ignore the LOD are classified as positive if there are more than the minimum number of events in at least two of the three MRD tests and the average proportion of CLL cells is above 0.01%. Results that use the LOD are classified as positive if there are more than the minimum number of events in at least two of the three MRD tests and the average proportion of CLL cells is above 0.01% and is also above the limit of detection for that sample.
cytometry and PCR (Spearman rank R ¼ 0.934, Po0.0001, regression line gradient ¼ 1.04).
Discussion
MRD analysis is increasingly used to assess response to therapy for patients with CLL. The results of this study demonstrate that, in most cases MRD analysis for response assessment can be reliably performed using peripheral blood samples. We have developed a set of reagents and associated analysis protocol for the detection of CLL cells in peripheral blood and bone marrow during or after therapy. The assay is suitable for the detection of disease at the level of 0.01% if sufficient cells are acquired and an appropriate preparation and gating procedures are followed. Cells should be prepared by a whole-blood lysis method with or without fixative (e.g. ammonium chloride lysis, FACSLyse, etc) to allow quantitative enumeration of CLL cells. Approaches such as density-gradient centrifugation should not be used for CLL MRD detection because the variable recovery of cell subsets makes quantitative analysis inaccurate and irreproducible, particularly in bone marrow samples. Absolute enumeration, using a quantitative bead system, may be of use for peripheral blood samples. It will be necessary to stain at least one million cells, and preferably two million for each test if using FACSLyse or equivalent. The tests comprise:
Optimal antibody clones and conjugates are listed with the complete gating strategy and other supporting documentation is available at www.cllmrd.org.
Test (1) is not required for quantitative CLL MRD analysis but allows confirmation of clonality and comparison with historical approaches. Test (1) alone may be sufficient to demonstrate residual disease, for example in patients treated with singleagent chemotherapy or in the peripheral blood of patients during therapy. It may be possible to use this approach to screen samples and avoid extended analysis in cases with clear evidence of residual disease where all the B cells are CD5 þ with light-chain restriction. Further work is underway to identify a specific procedure for using this combination as an MRD screening test. It is important to note that if Test (1) does not demonstrate clear evidence of residual disease, this does not imply MRD negativity and a complete MRD panel is required.
Test (2) is used for enumeration of CD19 þ B cells as a proportion of total CD45 þ leucocytes and assessment of the contamination rate within the B-cell gate using CD3 expression to identify events that are definitely not B cells. CD14 can also be used as a gating control and may help to delineate B cells from monocytes in a CD19 vs side scatter plot. Alternatively, CD56 may be used if quantitation of NK-cells is of interest. Test (2) or an equivalent is required to provide a control for CLL cell enumeration and to define the limit of detection. The advantage of using CD3 instead of an isotype-matched antibody is that T-cell:B-cell doublets, which would appear phenotypically similar to CLL cells, may be identified by CD3 expression but would not necessarily be detected by an isotype-matched control reagent. Test (2) should only be omitted if suitable alternative controls are incorporated in the assay and in addition the results are compared directly with a more sensitive reference technique, that is RQ-ASO IgH-PCR.
Tests (3) (4) (5) are used to detect CLL cells in a polyclonal background. Individual tests may be insensitive for patients with an atypical phenotype, that is with strong CD20/CD79b expression or weak CD5/CD43 expression; knowledge of the pre-treatment phenotype is therefore helpful for analysis. Accurate analysis requires the acquisition of at least 5 00 000 leucocytes in all tubes. The limit of detection should be below 0.01%; if the limit of detection is above this level then an attempt should be made to re-analyse or re-acquire with sufficient events although this may not be possible in poor Figure 4 There is a close correlation between RQ-ASO IgH-PCR and flow cytometry for the detection of CLL cells above 0.01% of leucocytes. RQ-ASO IgH-PCR has a greater sensitivity with a limit of detection below 0.001%.
quality or hypocellular samples. The procedure for calculating the level of MRD is provided within the Supplementary Information and is also available in the 'operating procedures' section of the www.cllmrd.org website (see also http://www. ericll.org/projects/index.php). The consensus for reporting the level of MRD in CLL is 'CLL cells ¼ x% of leucocytes (limit of detection ¼ y%)' for MRD-positive samples or 'CLL cells oy% of leucocytes' for MRD-negative samples. If the limit of detection is above 0.01% then a comment should be made indicating why the sample is inadequate. Based on the data analysed from this study, one would expect over 95% accuracy for detection of typical CLL cells at the 0.01% level or above. This reporting convention can also be used for RQ-ASO IgH-PCR results, which would make interpretation of MRD results much simpler.
The antibody combinations identified provide a good platform for MRD assessment, but education and experience is at least as important. The operating procedure alone can provide a significant improvement in accuracy and specificity for experienced flow cytometry operators. However, there will undoubtedly be a need for a quality control scheme for laboratories providing CLL MRD flow analysis.
The data demonstrate that peripheral blood is suitable for response assessment and in some cases has more readily detectable disease than the bone marrow. This may occur during a regenerative phase when there are large numbers of normal myeloid and lymphoid progenitors in the bone marrow. In this setting, equivalent levels of CLL in blood and marrow will equate to a lower CLL proportion in the marrow because of the higher levels of normal cells. However, bone marrow analysis is clearly required for assessing MRD levels during treatment with monoclonal antibodies. In addition, bone marrow may be required for response assessment after antibody-containing regimes as both normal and neoplastic B cells may be depleted in the peripheral blood for several months after cessation of alemtuzumab treatment but present in the bone marrow. 10 Similar recovery kinetics may be seen with rituximab-containing regimens (AC Rawstron and P Hillmen, unpublished data, March 2006). A lack of B cells in the peripheral blood at response assessment may indicate that the patient is effectively still on antibody therapy. Therefore, a peripheral blood sample taken after antibody therapy that contains no B cells is likely to be unsuitable for response assessment, and either a bone marrow or a repeated peripheral blood in 3 months would be required. It is likely that the significance of the MRD level will vary according to the specific therapy, sample type and timepoint. The MRD assay described here is intended to be independent of therapy, sample type and time-point but it is important to note that the relevance and application of MRD results will require testing in each specific situation.
As expected, RQ-ASO IgH-PCR is more sensitive than MRD flow cytometry. It is ideally suited for retrospective analysis in clinical trials for several reasons: the approach has a high level of sensitivity in most patients and samples do not need to be fresh and can be shipped to a single centre for analysis. The major cost is in the sequencing of the IgH gene to generate patient-specific primers but the sequence analysis would have to be performed anyway in most clinical trials in order to assess VH mutational status as a prognostic marker. However, because of the slow turn-around time it is unlikely to be the method of choice for routine assessment of patients undergoing treatment outside of clinical trials. The MRD flow assay developed here is broadly applicable and can be performed at any laboratory with a four-colour flow cytometer. The assay can detect residual disease at the level of 0.01%, which is highly predictive of outcome in NCI-remission patients, [9] [10] [11] [12] with accuracy above 95% and minimal false-positive results for patients with typical CLL. This approach has been applied to the majority of therapeutic approaches however further prospective studies will be required to demonstrate the applicability of this approach in specific treatment regimes. Future improvements are likely to involve the development of quality control schemes and sixcolour approaches that are unlikely to improve the limit of detection but could improve sensitivity, particularly for patients with phenotypically atypical CLL and potentially allow a simpler gating strategy.
